These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 19434004)
21. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409 [TBL] [Abstract][Full Text] [Related]
22. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Golas JM; Lucas J; Etienne C; Golas J; Discafani C; Sridharan L; Boghaert E; Arndt K; Ye F; Boschelli DH; Li F; Titsch C; Huselton C; Chaudhary I; Boschelli F Cancer Res; 2005 Jun; 65(12):5358-64. PubMed ID: 15958584 [TBL] [Abstract][Full Text] [Related]
23. [SRC kinases in tumor therapy]. Dempke W; Zippel R Med Klin (Munich); 2010 Oct; 105(10):711-5. PubMed ID: 20981590 [TBL] [Abstract][Full Text] [Related]
24. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Vultur A; Buettner R; Kowolik C; Liang W; Smith D; Boschelli F; Jove R Mol Cancer Ther; 2008 May; 7(5):1185-94. PubMed ID: 18483306 [TBL] [Abstract][Full Text] [Related]
25. SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma. Tokuhisa Y; Lidsky ME; Toshimitsu H; Turley RS; Beasley GM; Ueno T; Sharma K; Augustine CK; Tyler DS Ann Surg Oncol; 2014 Mar; 21(3):1024-30. PubMed ID: 24281418 [TBL] [Abstract][Full Text] [Related]
26. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Levitt JM; Yamashita H; Jian W; Lerner SP; Sonpavde G Mol Cancer Ther; 2010 May; 9(5):1128-35. PubMed ID: 20406945 [TBL] [Abstract][Full Text] [Related]
27. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412 [TBL] [Abstract][Full Text] [Related]
28. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894 [TBL] [Abstract][Full Text] [Related]
29. SRC signaling is crucial in the growth of synovial sarcoma cells. Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575 [TBL] [Abstract][Full Text] [Related]
30. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer. Segrelles C; Contreras D; Navarro EM; Gutiérrez-Muñoz C; García-Escudero R; Paramio JM; Lorz C Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933569 [TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Puttini M; Coluccia AM; Boschelli F; Cleris L; Marchesi E; Donella-Deana A; Ahmed S; Redaelli S; Piazza R; Magistroni V; Andreoni F; Scapozza L; Formelli F; Gambacorti-Passerini C Cancer Res; 2006 Dec; 66(23):11314-22. PubMed ID: 17114238 [TBL] [Abstract][Full Text] [Related]
33. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells. Kim EM; Mueller K; Gartner E; Boerner J J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511 [TBL] [Abstract][Full Text] [Related]
34. Bosutinib treatment for Philadelphia chromosome-positive leukemias. Bethelmie-Bryan B; Lord K; Holloway S; Khoury HJ Future Oncol; 2014 Feb; 10(2):179-85. PubMed ID: 24490604 [TBL] [Abstract][Full Text] [Related]
35. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097 [TBL] [Abstract][Full Text] [Related]
36. Current status of SRC inhibitors in solid tumor malignancies. Puls LN; Eadens M; Messersmith W Oncologist; 2011; 16(5):566-78. PubMed ID: 21521831 [TBL] [Abstract][Full Text] [Related]
37. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity. Teng Y; Cai Y; Pi W; Gao L; Shay C J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127 [TBL] [Abstract][Full Text] [Related]
38. HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib. deBlacam C; Byrne C; Hughes E; McIlroy M; Bane F; Hill AD; Young LS Br J Cancer; 2011 Jun; 105(1):118-23. PubMed ID: 21654685 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Buettner R; Mesa T; Vultur A; Lee F; Jove R Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823 [TBL] [Abstract][Full Text] [Related]
40. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling. Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]